Physician profile
Neema Mafi
NPI 1558679142
$995.13
in general payments reported to CMS, 2019-2025
7 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2022: $141 · 2023: $76.46 · 2024: $137 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.11 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $225.29 | 2019 | |
| Astellas Pharma US INC | $179.93 | 2019-2025 | |
| Gilead Sciences, INC. | $156.45 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.80 | 2022 | |
| Paratek Pharmaceuticals, INC. | $137.94 | 2023-2025 | Nuzyra |
| Amgen INC. | $133.81 | 2025 | Krystexxa |
| Aimmune Therapeutics, INC. | $20.91 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neema Mafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.